English
French
Wegovy, a highly discussed weight loss medication in Hollywood, has now become accessible in the UK
Wegovy, also known as semaglutide, is making its debut in the UK through a controlled and limited introduction. As of September 4, this weight loss injection is available through specialized NHS weight management services, provided in conjunction with a reduced-calorie diet and exercise regimen.
To qualify for Wegovy, individuals should have a body mass index (BMI) exceeding 30 or a BMI of over 27, combined with at least one weight-related co-morbidity, where obesity contributes to the development of other health conditions.
The National Institute for Care and Excellence (NICE) granted approval for Wegovy's NHS usage earlier this year, with a stipulation that it should be employed for a maximum duration of two years.
Novo Nordisk, the manufacturer of Wegovy, believes that its introduction in the UK will offer an additional option to support individuals grappling with obesity.
The UK government had previously allocated £40 million to pilot schemes aimed at expanding access to specialized weight management services, as part of a broader effort to combat obesity. Prime Minister Rishi Sunak has referred to Wegovy as a "game-changer" in this context.
Wegovy is typically prescribed as a medication for type 2 diabetes, primarily functioning to reduce appetite. It shares the same active ingredient as Ozempic, a drug that has garnered attention for its reported use by celebrities to manage their weight. Nevertheless, medical experts have cautioned that using Wegovy as a weight loss aid without proper medical supervision may carry potential side effects. Dr. Amir Khan, in previous appearances on programs like Good Morning Britain and Lorraine, has offered guidance and advice on this matter.
